Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Sugar cut in fizzy drinks can prevent 3 lakh diabetes cases: Lancet
Cutting sugar in sweetened drinks by 40 percent can prevent over three lakh obesity-related Type 2 diabetes over the next two decades, a significant study has found.
- Read more about Oral contraceptive use doesn't lead to major birth defects
The use of oral contraceptive just before pregnancy is not associated with an increased risk of major birth defects, says a study.
- Read more about Low sunlight exposure increases cancer risk
Persons residing at higher latitudes, with lower sunlight exposure and greater prevalence of vitamin D deficiency, are at greater risk of developing cancer, including leukemia, a type of blood cancer, new research reveals.
- Read more about USFDA warns Cadila on lack of audit trails, torn notebooks, product mix-ups
Torn notebook recording deficiencies, lack of batch manufacturing records, use of unofficial notebooks, lack of audit trails on operation of computer systems, product mix-ups due to manufacturing deficiencies are some of the violations found by USFDA at Cadila Healthcare Ltd's two plants.
- Read more about Cipla to commercialize BioQ’s Ropivacaine Infusion System in India
BioQ Pharma and Cipla the signed of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India.

[adsense:336x280:8701650588]
- Read more about BioQ Pharma Enter into an Agreement with Cipla
BioQ Pharma Incorporated, a specialty pharmaceutical company focused on the development and commercialization of single-use, large-volume ready-to-use infusible pharmaceuticals, and Cipla Limited, “Cipla,” a global pharmaceutical company that uses cutting edge technology and innovation to meet the everyday needs of all patients, announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India.
- Read more about Gilead Get FDA Priority Review Designation for Sofosbuvir/Velpatasvir
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF)
- Read more about Lupin Launches Generic Ortho Tri-Cyclen® Lo Tablets in the US
Pharma Major Lupin Limited (Lupin) announced that its US subsidiary Lupin Pharmaceutical Inc. has launched its Tri-Lo-Marzia™ Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) having received approval from the United States Food and Drug Administration (FDA) to market a generic equivalent of Janssen Pharmaceuticals Inc. (Janssen) Ortho Tri-Cyclen® Lo Tablets, (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg).
- Read more about Pre registration require for CDSCO's SUGAM Portal
For security purposes and to avoid spam health ministry decided that the applicants have to pre-register themselves on online licensing portal - the “SUGAM”. This portal is intended for those who desire to file applications for various services rendered by Central Drugs Standard Control Organization (CDSCO).
- Read more about Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
Novartis announced today a collaboration with Qualcomm Incorporated through its subsidiary, Qualcomm Life, Inc., in digital innovation with the Breezhaler(TM) inhaler device to treat COPD. Under this collaboration, Qualcomm Life will provide the technology solution for the connectivity of the next generation of the Breezhaler(TM) inhaler, a device used for Novartis' portfolio of COPD treatments of Onbrez(TM) Breezhaler Seebri(TM) Breezhaler, and Ultibro(TM) Breezhaler, the leading LABA/LAMA treatment.